P2RX5 and breast cancer: A previous study showed altered purinergic receptor-Ca2+ signaling in endothelial growth factor (EGF)-induced epithelial–mesenchymal transition (EMT) and later in hypoxia-induced EMT in breast cancer cells [18,19].